Homozygous deletion of an EGR2 enhancer in congenital amyelinating neuropathy

Ann Neurol. 2012 May;71(5):719-23. doi: 10.1002/ana.23527.

Abstract

The transcription factor EGR2 is expressed in Schwann cells, where it controls peripheral nerve myelination. Mutations of EGR2 have been found in patients with congenital hypomyelinating neuropathy or Charcot-Marie-Tooth disease type 1D. In a patient with congenital amyelinating neuropathy, we observed pathological abnormalities recapitulating the peripheral nervous system phenotype of homozygous Egr2-null mice. This patient, born from consanguineous parents, showed no EGR2 immunoreactivity in Schwann cells and harbored a homozygous 10.7-kilobase-long deletion encompassing a myelin-specific enhancer of EGR2. This regulatory mutation is the first genetic abnormality associated with congenital amyelinating neuropathy in humans.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Charcot-Marie-Tooth Disease / genetics*
  • Charcot-Marie-Tooth Disease / pathology*
  • Early Growth Response Protein 2 / genetics*
  • Enhancer Elements, Genetic / genetics*
  • Female
  • Homozygote
  • Humans
  • Infant
  • Infant, Newborn
  • Molecular Sequence Data
  • Myelin Sheath / pathology*
  • Pedigree
  • Polymerase Chain Reaction
  • Sequence Deletion

Substances

  • EGR2 protein, human
  • Early Growth Response Protein 2

Supplementary concepts

  • Charcot-Marie-Tooth disease, Type 4E